|View printer-friendly version|
Spring Bank Pharmaceuticals Reports 2019 Fourth Quarter and Full-Year Financial Results
“In January, we made the difficult decision to discontinue our development efforts in the field of chronic hepatitis B virus (HBV). We are moving forward by continuing to advance our internally-developed product candidates in the fields of immuno-oncology and inflammatory diseases,” said
Mr. Driscoll continued, “With our cash balance of
2019 Highlights and Potential 2020 Milestones
Year-End and Fourth Quarter Financial Results
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether the results of the company’s trials will warrant submission for approval from the
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.